Skip to main content
PLOS Medicine logoLink to PLOS Medicine
. 2024 Mar 28;21(3):e1004371. doi: 10.1371/journal.pmed.1004371

Impact of the UK soft drinks industry levy on health and health inequalities in children and adolescents in England: An interrupted time series analysis and population health modelling study

Linda J Cobiac 1, Nina T Rogers 2, Jean Adams 2, Steven Cummins 3, Richard Smith 4, Oliver Mytton 5, Martin White 2, Peter Scarborough 6,*
PMCID: PMC11008889  PMID: 38547319

Abstract

Background

The soft drinks industry levy (SDIL) in the United Kingdom has led to a significant reduction in household purchasing of sugar in drinks. In this study, we examined the potential medium- and long-term implications for health and health inequalities among children and adolescents in England.

Methods and findings

We conducted a controlled interrupted time series analysis to measure the effects of the SDIL on the amount of sugar per household per week from soft drinks purchased, 19 months post implementation and by index of multiple deprivation (IMD) quintile in England. We modelled the effect of observed sugar reduction on body mass index (BMI), dental caries, and quality-adjusted life years (QALYs) in children and adolescents (0 to 17 years) by IMD quintile over the first 10 years following announcement (March 2016) and implementation (April 2018) of the SDIL. Using a lifetable model, we simulated the potential long-term impact of these changes on life expectancy for the current birth cohort and, using regression models with results from the IMD-specific lifetable models, we calculated the impact of the SDIL on the slope index of inequality (SII) in life expectancy. The SDIL was found to have reduced sugar from purchased drinks in England by 15 g/household/week (95% confidence interval: −10.3 to −19.7). The model predicts these reductions in sugar will lead to 3,600 (95% uncertainty interval: 946 to 6,330) fewer dental caries and 64,100 (54,400 to 73,400) fewer children and adolescents classified as overweight or obese, in the first 10 years after implementation. The changes in sugar purchasing and predicted impacts on health are largest for children and adolescents in the most deprived areas (Q1: 11,000 QALYs [8,370 to 14,100] and Q2: 7,760 QALYs [5,730 to 9,970]), while children and adolescents in less deprived areas will likely experience much smaller simulated effects (Q3: −1,830 QALYs [−3,260 to −501], Q4: 652 QALYs [−336 to 1,680], Q5: 1,860 QALYs [929 to 2,890]). If the simulated effects of the SDIL are sustained over the life course, it is predicted there will be a small but significant reduction in slope index of inequality: 0.76% (95% uncertainty interval: −0.9 to −0.62) for females and 0.94% (−1.1 to −0.76) for males.

Conclusions

We predict that the SDIL will lead to medium-term reductions in dental caries and overweight/obesity, and long-term improvements in life expectancy, with the greatest benefits projected for children and adolescents from more deprived areas. This study provides evidence that the SDIL could narrow health inequalities for children and adolescents in England.


Peter Scarborough and colleagues investigate how the UK Soft Drink Industry Levy has impacted dental caries, obesity, life expectancy and quality of life in children and adolescents living in England.

Author summary

Why was this study done?

  • The UK soft drink industry levy (SDIL) has led to reduction in household purchasing of sugar in drinks, but it is not known what implications this may have for addressing high rates of dental caries and obesity among children and adolescents in England, particularly those in the more deprived areas of the country that carry a higher burden of poor health.

What did the researchers do and find?

  • We performed a controlled interrupted time series analysis to measure the effects of the SDIL on the amount of sugar per household per week from soft drinks purchased, by index of multiple deprivation (IMD) quintile; then modelled the medium- to long-term impacts this may have on dental caries, obesity, life expectancy and quality of life for children and adolescents in England.

  • We found a significant reduction in purchased sugar in England overall; with the largest absolute reductions in the 2 most deprived quintiles; a small, but significant, increase in purchased sugar in the middle quintile; and small significant reductions in sugar in the 2 least deprived quintiles.

  • The modelling predicted that children and adolescents in the most deprived areas of England would experience the biggest gains in health, including fewer dental caries, less obesity, and improved quality of life and life expectancy.

  • Children and adolescents in less deprived areas will also experience health benefits, but on a smaller scale, leading to a small but significant reduction in health inequality in England.

What do these findings mean?

  • The study indicates that the SDIL could improve health and narrow health inequalities for children and adolescents in England.

  • The impact may be underestimated since our data only included drinks purchased and brought into the home. We additionally assumed that trends in drink purchasing before the SDIL announcement would have continued and that the effects of the SDIL on drink purchasing can be sustained.

Introduction

A soft drinks industry levy (SDIL) was introduced in the United Kingdom in April 2018 to encourage soft drink manufacturers to reduce the amount of sugar in soft drinks available for purchase. It is a tiered levy of £0.18 per litre on drinks with between 5 g and 8 g of total sugars per 100 ml, and £0.24 per litre on drinks with 8 g or more of total sugars per 100 ml [1]. Drinks with less than 5 g per 100 ml of sugar attract no levy, and milk-based drinks, pure fruit juices, low-alcohol drinks (zero alcohol versions of drinks that are marketed as specific alternatives to high alcohol drinks, or drinks that have had alcohol removed from them until they have got less than 1.2% alcohol by volume) and those sold by importers or manufacturers with a volume of less than 1 million litres per year are exempt. Interrupted time series analyses of trends before and after the SDIL announcement in 2016 and implementation in 2018 found that the volume of soft drinks purchased increased by 188.8 ml (95% confidence interval: 30.7 to 346.9) per household per week, at 1 year after implementation, but that the amount of sugar in those drinks was 8.0 g (2.4 to 13.6) lower per household per week [2].

The SDIL provides incentives for drink reformulation with the aim of reducing population sugar intake and was primarily motivated by the UK government’s plans to address the high prevalence of childhood obesity [3,4]. Free sugar intake is over double the recommended intake (<5% of total energy [5]) in children and adolescents [6], and sugar-sweetened beverages (SSBs) are a key contributor to the excess [7]. Consumption of SSBs is associated with increased weight gain in children and adolescents [8,9] as well as higher rates of dental caries [10]. In addition, there are strong and persistent socioeconomic gradients in both childhood obesity [11,12] and tooth decay in the UK [13,14]. Despite regular recommendations for action on health inequalities since the 1980s [15,16], there has been little change in key measures such as life expectancy [17]. A child born today in the most deprived areas of England can expect to live 9.4 years less if they are male or 7.6 years less if they are female, than had they been born into an area of least deprivation. In addition to having a shorter life they will also, on average, spend 12 more years in a poor state of health [18]. In recent years, improvements in life expectancy have stalled and even reversed in many areas of England, and the inequality has widened, a situation exacerbated by the COVID-19 pandemic [1921].

A 2016 systematic review of the effect of SSB taxes on socioeconomic differences in health concluded that a tax on SSBs would likely lead to changes in population weight of a similar magnitude for all socioeconomic groups or slightly better outcomes for lower compared to higher socioeconomic groups [22]. Additionally, it concluded that SSB taxes would likely be financially regressive to a small degree (up to 1% or 0.6% of annual household income for low- and high-income households, respectively). Globally, as of May 2022, 53 countries had implemented some type of SSB tax [23], but there have been very few evaluations of the real-world impacts on different socioeconomic groups. Evaluation of an SSB tax in Mexico showed that it had led to larger reductions in purchases among lower socioeconomic groups [24,25]. But an evaluation of an SSB tax in Chile found larger reductions in purchases among higher socioeconomic groups [26,27].

In this study, we measure the impact of the UK SDIL on household sugar purchasing stratified by area-level deprivation. We then model the future impact of sugar reduction on health and health inequalities for children and adolescents in England. Over the medium-term (10 years), we model the impact of the SDIL on overweight/obesity, dental caries and quality-adjusted life years (QALYs), and over the long-term (lifetime), we model how sustained reductions in sugar consumption are likely to impact on the inequality in life expectancy and quality-adjusted life expectancy for the current birth cohort.

Methods

Analysing the effect of the SDIL on household weekly sugar purchasing

We conducted controlled interrupted time series analyses of sugar from drinks purchased for at-home consumption in England, following methods described by Rogers and colleagues [2]. For this study, we stratified the analyses by quintile of index of multiple deprivation (IMD)—an area-level measure of socioeconomic deprivation [28]. Due to differences in measurement of deprivation across Great Britain, we focused the stratified analyses on purchasing data for England only.

The analyses used household purchasing data collected between March 2014 and November 2019 by Kantar Fast Moving Consumer Goods panel, a market research company. In this data set, participating households are asked to scan the barcodes of food and drink purchases that are brought into the home. These purchasing data are uploaded weekly and linked to data on nutritional content. Household demographic information is updated annually, and participating households receive gift vouchers equivalent to £100 ($122; €112) annually. The panel data are in the form of a line list of purchases rather than a household study. Proprietary weights (called grossupweight) are applied at the level of the purchases rather than the households. Other information attached to the line list of purchases includes the week of purchase, product descriptions, the amount of sugar in grams per 100 mls, overall volume, and a unique household identifier. The mean weekly number of households in the panel in England was 17,717. To account for possible substitution effects, we included data on purchases of all drinks irrespective of whether they were liable for the levy or not. The drink categories included soft drinks, milk and milk-based drinks, no-added-sugar fruit juice, and drinks sold as powders. Data on purchases of toiletries (shampoo, hair conditioner, and liquid soap categories) were included as a control group for the analyses. We included weekly household purchasing of toiletries (liquid soap, shampoo, and hair conditioner) as a nonequivalent control group to account for background trends in household purchases. Toiletries were selected as a suitable control group because purchasing is unlikely to be influenced by seasonality or confounders, including socioeconomic position [29].

The IMD classification variable was determined by Kantar based on postcode of the household. IMD information was not provided for all households in the Kantar data set. The missing IMD information primarily affected data at the start of the collection period, i.e., before announcement of the SDIL. Given the possibility that the data were not missing at random and to minimise data loss, we imputed missing IMD values using multiple imputation by chained equations in R version 4.1.0. Variables in the imputation models included gross household income, social class, highest educational qualification, geographical region, age of main household member, and presence of children in the household.

We used the product names and product groups defined by Kantar to assign products to drinks or toiletries groups for analyses. The outcome variable for the drinks analyses was the average weekly weight of sugar in purchased drinks (g/household/week), which we estimated from the purchased products, their sugar content and volume, and the number of households at each weekly time point. We included weekly household purchasing of toiletries as a control group to account for background trends in household purchases. We applied a proprietary weight provided by Kantar so that the data reflected the size, demographic and socioeconomic characteristics of the population of Great Britain. For the stratified analyses, we further adjusted the outcome variable to reflect the data subgroup. This included adjustments of 0.865 (the proportion of the population of Great Britain in England) and 0.2 (the proportion of the England population in an IMD quintile).

We included data collected between March 2014 (24 months before announcement of the SDIL in March 2016) and November 2019 (19 months after implementation of the SDIL in April 2018). We ended follow-up at 19 months after SDIL implementation, rather than 24 months as initially intended, due to the possibility of changes in household purchasing behaviour with Britain’s exit from the European Union in December 2019 and the subsequent COVID-19 pandemic and lockdowns in early 2020.

In the controlled interrupted time series analyses (S1 Text), we allowed for changes in both slope and level in the outcome variable [30]. Following methods described by Rogers and colleagues [2], the analyses were conducted using a controlled generalised least squares model approach, with an autocorrelation-moving average correlation structure, where the autoregressive order (p) and moving average order (q) were selected to minimise the Akaike information criterion value. In addition to binary variables for both the announcement (in March 2016 –week 108) and implementation (in April 2018 –week 214) of the SDIL, we included dummy variables to reflect changes in purchases during the months of December and January, and we included average UK monthly temperature to adjust for potential temperature-related variability in drink purchases. The impact of the SDIL on sugar purchasing was estimated from the difference between the modelled weight of sugar in purchased drinks at the end of data series (November 2019 –week 295) and the counterfactual value, which we calculated assuming there had been no announcement or implementation of the SDIL. Confidence intervals were calculated from standard errors, which we estimated using the delta method [31].

Modelling the health impacts of sugar reduction

To model the impacts of sugar reduction on health, we constructed a lifetable model to simulate years of life lived and life expectancy of the English population (Fig 1). We ran the model with a starting population of all children and adolescents (0 to 17 years) in England in 2015 [32] and added future birth cohorts based on population projections from the Office for National Statistics [33]. At each year of simulation in the lifetable model, those alive were exposed to a risk of death (due to any cause) and experienced a quality of life, which was quantified by a utility weight ranging from 0 (death) to 1 (full health). The lifetable model was run separately by age group (0, 1–4, 5–9, 10–14…, 85–89, 90+), sex (male, female), and quintile of deprivation. Deprivation quintiles were based on the IMD and defined from 1 (most deprived) through to 5 (least deprived).

Fig 1. The lifetable model structure.

Fig 1

Fig 1 illustrates how we modelled the effects of changes in sugar purchasing on health outcomes in the lifetable model. We evaluated the population health impacts of the SDIL by simulating 2 scenarios in the lifetable model: a base case scenario, in which we assumed there had been no implementation of the SDIL, and an intervention scenario, which reflected the actual SDIL implementation in 2016 and assumed no future changes to the levy. The difference between these 2 scenarios was attributed to the sugar-reduction effects of the SDIL.

Below we provide an overview of methods used to calculate each health outcome, with additional details on the calculations and data inputs provided in an accompanying supplement (S2 Text).

From the effects on household purchasing of sugar, we estimated an average per person change in sugar consumption in each IMD quintile, assuming that food purchases are a reasonable proxy for dietary intake of sugar [34,35], and that there is an average of 2.4 people per household in England [36].

To model the impact of reduced sugar consumption on body weight, we converted sugar to calorie consumption [37] and determined the effect of reduced energy intake on body weight using energy balance equations [38,39]. Here, we assume that the reduced consumption of calories from all drinks (estimated from the interrupted time series analysis) is not associated with changes in calorie consumption from solid foods, which is supported by evidence that calories from soft drinks have limited impact on satiety [40], on observed elasticities of demand for soft drinks [41], and on the previous interrupted time series analyses of the SDIL for Great Britain, which showed no overall substitution to confectionary products [2]. From this we determined change in body mass index (BMI) and prevalence of overweight and obesity using baseline data on the distribution of BMI by age, sex, and IMD quintile from the Health Survey for England [42]. Overweight and obesity were defined using International Obesity Taskforce definitions [43].

To model the impact of reduced sugar consumption on dental caries, we estimated the reduction in decayed, missing, and filled teeth that are deciduous (dmft) or permanent (DMFT) based on a dose-response relationship between sugar intake and dental caries [44]. Baseline dmft and DMFT rates were derived, by age and IMD quintile, from data collected in the Children’s Dental Health Survey 2013 and the Adult Dental Health Survey 2009 [45,46].

The mortality rates in the lifetable model influence how many people are alive at each year of a simulation. We modelled the impact of changes in BMI on all-cause mortality rates, by age, sex, and IMD quintile, using hazard ratios derived from meta-analysis of prospective cohorts studies [47]. From these calculations we determined impact of the SDIL on life years and life expectancy by IMD quintile.

We modelled the impact of the SDIL on QALYs and quality-adjusted life expectancy using health state utility weights. We applied utility weights to reflect background quality of life by age, sex, and IMD quintile, from an analysis of EQ-5D data from the Health Survey for England [48]. Impacts on quality of life from changes in BMI and dental caries were determined using health state utilities for these conditions [4951].

Simulation of medium-term health impacts

We ran the lifetable model over a ten-year time horizon (2015 to 2025) to determine medium-term impacts of the SDIL on dental caries, prevalence of overweight/obesity and QALYs. For these analyses, we ran an open cohort simulation to determine outcomes for all children and adolescents who were alive or born within the ten-year time horizon. In an open cohort analysis, new birth cohorts are added as time progresses, so that at each time point the modelled population represents the whole population of children and adolescents alive at that point in time.

Simulation of long-term health impacts

We modelled long-term impacts of the SDIL on life expectancy and quality-adjusted life expectancy by running a closed cohort simulation in the lifetable model. A closed cohort analysis only follows up population cohorts present at the start of the simulation (i.e., no future birth cohorts are added through time). In this simulation, we followed a cohort of all babies born in 2015 until all had died or reached 100 years of age. We assumed that the reduction in sugar consumption, which we derived from the interrupted time series analyses estimates of changes in sugar purchased in drinks, would be maintained across the life course.

To model the long-term impact of the SDIL on health inequality, we estimated the change in slope index of inequality (SII) [52], which is a commonly used metric of health inequality in England [53]. An SII reflects the difference in life expectancy between the most and least deprived groups in the population, thus an increase in SII reflects a widening of health inequalities, while a decrease in SII reflects a narrowing of health inequalities [54]. We calculated the SII by linear regression of life expectancy or quality-adjusted life expectancy (outcome variable) and IMD quintile (predictor variable). The regression coefficient reflected the SII.

Probabilistic sensitivity analysis

We performed probabilistic sensitivity analyses to calculate 95% uncertainty intervals around all modelled estimates, drawing from uncertainty distributions around analytical input parameters (hazard ratios, health state utilities, and sugar dose-response relationships) and the SDIL effect in reducing sugar. Further details on these input parameters can be found in an accompanying supplement (S2 Text).

Results

Impact on purchased sugar in drinks

Table 1 shows the mean weight of sugar purchased in drinks per household per week in England in the week before SDIL announcement, in the week before SDIL implementation, and at the end of study. Before announcement of the SDIL, the mean weekly weight of purchased sugar was highest in the 2 most deprived IMD quintiles. Sugar purchasing declined in all groups over the course of the study, but the 2 most deprived IMD quintiles were still observed to have the highest levels of sugar purchasing at the end of the study.

Table 1. Absolute change in purchased sugar from drinks.

IMD Weight of sugar in purchased drinks (g/household/week)
Observed mean in the week prior to SDIL announcement (week 108) Observed mean in the week prior to SDIL implementation (week 214) Observed mean at study end (week 295) Predicted counterfactual* mean at study end (week 295) Difference in mean sugar at study end (week 295)
Q1 354.0 321.7 282.1 319.6 −37.5 (−31.5, −43.5)
Q2 372.3 353.2 308.5 337.7 −29.2 (−23.4, −35.0)
Q3 339.9 319.8 271.4 263.5 7.98 (2.23, 13.7)
Q4 332.8 302.1 267.7 271.4 −3.76 (1.85, −9.37)
Q5 308.5 285.7 255.0 265.9 −10.9 (−5.72, −16.0)
All quintiles 341.6 316.4 276.9 291.9 −15.0 (−10.3, −19.7)

* Counterfactual scenario is based on pre-announcement trends and therefore assumes there has been no announcement or implementation of the SDIL.

NB. IMD quintiles: Q1 (most deprived)–Q5 (least deprived). Values are mean and 95% confidence intervals.

IMD, index of multiple deprivation; SDIL, soft drinks industry levy.

Overall, there was a 15.0 g/household/week (95% confidence interval: 10.3 to 19.7) reduction in purchased sugar in England, compared to the counterfactual scenario in which it was assumed there had been no announcement or implementation of the SDIL (Table 1 and S3 Text). The simulated effect of the SDIL varied by quintile of deprivation. The largest absolute reductions in purchased sugar were observed in the 2 most deprived quintiles; there was a small, but significant, increase in purchased sugar in the middle quintile; and small significant reductions in sugar in the 2 least deprived quintiles.

S3 Text presents the same results, but without imputation of missing data. The household purchasing data set had a high level of missing IMD values at the beginning of the study period, but missing data were much lower by the end of the study period. Therefore, without imputation of missing data, the level of sugar purchasing appears to be increasing over time, inflating the difference between the observed and counterfactual trends, and leading to an overestimate of the effects of the SDIL on sugar purchasing. With imputation of the missing data, this inflation of the difference between counterfactual and observed data disappears, giving a more accurate (and conservative) estimate of the SDIL effect on sugar purchasing.

Medium-term health impacts in children and adolescents

In the first 10 years following implementation of the SDIL, the model predicts there will be an annual average reduction of 3,600 (95% uncertainty interval: 946 to 6,330) dental caries and 64,100 (54,400 to 73,400) children and adolescents classified as overweight or obese (Table 2). This equates to a 0.59 percentage point (0.50 to 0.68) reduction in prevalence of overweight and obesity. The simulated effects are similar for males and females (S3 Text).

Table 2. Predicted impact on number of dental caries and cases of overweight and obesity, in children and adolescents, in the first 10 years following implementation of the SDIL.

IMD Dental caries (number of dmft/DMFT) Overweight (number of cases) Obese (number of cases)
Q1 −2,240 (−3,990, −579) −22,800 (−26,400, −19,200) −13,000 (−15,100, −11,000)
Q2 −1,270 (−2,230, −325) −18,000 (−21,500, −14,500) −7,850 (−9,350, −6,340)
Q3 280 (37.3, 627) 4,350 (1,220, 7,420) 1,770 (497, 3,030)
Q4 −101 (−310, 52.8) −1,660 (−4,140, 857) −554 (−1,380, 287)
Q5 −274 (−550, −62.2) −4,920 (−7,250, −2,610) −1,470 (−2,160, −779)
All quintiles −3,600 (−6,330, −946) −43,000 (−49,500, −36,200) −21,100 (−24,000, −18,200)

NB. IMD quintiles: Q1 (most deprived)–Q5 (least deprived). Values are mean and 95% uncertainty intervals.

IMD, index of multiple deprivation; SDIL, soft drinks industry levy.

The total impact on quality of life is a 19,500 QALY (14,800 to 24,600) health gain for children and adolescents in England in the first 10 years after implementation of the SDIL. Due to the unequal effect of the SDIL on sugar purchasing, the health benefits are not equally distributed across all levels of deprivation. The most deprived quintiles are expected to benefit the most from improvements in health (Table 3). There are large significant health gains in the 2 most deprived quintiles (Q1: 11,000 QALYs [8,370 to 14,100] and Q2: 7,760 QALYs [5,730 to 9,970]), a small significant health loss for the middle quintile (Q3: −1,830 QALYs [−3,260 to −501]), nonsignificant health gain for the less deprived quintile (Q4: 652 QALYs [−336 to 1,680]), and a small significant health gain for the least deprived quintile (Q5: 1,860 QALYs [929 to 2,890]).

Table 3. Predicted impact on QALYs, in children and adolescents, in the first 10 years following implementation of the SDIL.

Change in quality-adjusted life years
IMD Female Male Total
Q1 5,980 (4,630, 7,550) 5,060 (3,720, 6,560) 11,000 (8,370, 14,100)
Q2 4,030 (3,010, 5,130) 3,740 (2,710, 4,860) 7,760 (5,730, 9,970)
Q3 −937 (−1,660, −259) −893 (−1,600, −242) −1,830 (−3,260, −501)
Q4 368 (−187, 946) 284 (−149, 741) 652 (−336, 1,680)
Q5 1,030 (522, 1,580) 830 (405, 1,310) 1,860 (929, 2,890)
All quintiles 10,500, (8,120, 13,000) 9,020 (6,640, 11,500) 19,500 (14,800, 24,600)

NB. IMD quintiles: Q1 (most deprived)–Q5 (least deprived). Values are mean and 95% uncertainty intervals.

IMD, index of multiple deprivation; QALY, quality-adjusted life year; SDIL, soft drinks industry levy.

Long-term impacts on health and health inequalities

If the SDIL impacts on sugar purchasing are sustained over the life course the model predicts small changes in life expectancy and quality-adjusted life expectancy in England (Table 4). Due to the unequal impacts of the SDIL on sugar purchasing across IMD quintiles, the life expectancy and quality-adjusted life expectancy impacts are not equally distributed across all levels of deprivation. The pattern is like the predicted distribution of QALY health gains and losses across the IMD quintiles; the model predicts the largest increases in life expectancy and quality-adjusted life expectancy in the 2 most deprived quintiles (Q1 and Q2), a small but significant decrease in the middle quintile (Q3), no significant effect in the less deprived quintile (Q4), and a small significant increase for the least deprived quintile (Q5).

Table 4. Average population increase in life expectancy and quality-adjusted life expectancy by IMD.

Change in life expectancy (days) Change in quality-adjusted life expectancy (days)
IMD Female Male Female Male
Q1 18 (15, 21) 31 (26, 36) 25 (20, 30) 32 (26, 39)
Q2 16 (13, 19) 21 (17, 25) 21 (16, 26) 23 (18, 29)
Q3 −3.3 (−5.7, −0.94) −5.3 (−9.1, −1.5) −5 (−8.7, −1.4) −6.1 (−11, −1.7)
Q4 1.3 (−0.65, 3.2) 2.4 (−1.2, 5.9) 2.1 (−1.1, 5.2) 2.7 (−1.4, 6.9)
Q5 4.0 (2.1, 5.8) 6.6 (3.5, 9.8) 6.2 (3.2, 9.3) 7.9 (4.1, 12)

NB. IMD quintiles: Q1 (most deprived)–Q5 (least deprived). Values are mean and 95% uncertainty intervals.

IMD, index of multiple deprivation.

Overall, the model predicts small but significant decreases in the SII in life expectancy and quality-adjusted life expectancy (Fig 2). For females, there is a 0.76 percentage point reduction ([95% uncertainty interval: −0.9 to −0.62]; −4.2 days [−5.0 to −3.5]) in SII for life expectancy and 0.54 percentage point reduction ([−0.67 to −0.42]; −5.7 days [−7.0 to −4.4]) in SII for quality-adjusted life expectancy. For males, there is a 0.94 percentage point reduction ([−1.1 to −0.76]; −6.6 days [−8.0 to −5.4]) in SII for life expectancy and 0.60 percentage point reduction ([−0.74 to −0.46]; −6.8 days [−8.5 to −5.3]) in SII for quality-adjusted life expectancy.

Fig 2. Change in slope index of inequality for life expectancy (purple) and quality-adjusted life expectancy (blue).

Fig 2

The shading reflects the distribution of the data, the dot symbol shows the mean, and the error bars show the 95% uncertainty interval.

Discussion

The UK government introduced the SDIL to address the high prevalence of childhood obesity [3,4]. Our modelling suggests that in the first 10 years after implementation, the SDIL will lead to substantial reductions in obesity and dental caries, and an overall health gain of 19,500 QALYs (0.56 QALYs per 1,000 population) for children and adolescents in England. The changes in sugar purchasing and predicted impacts on health are largest for children and adolescents in the most deprived areas (+11,000 QALYs in Q1 and +7,760 QALYs in Q2), while children and adolescents in less deprived areas will experience much smaller simulated effects (−1,830 QALYs in Q3, nonsignificant changes in Q4, and +1,860 QALYs in Q5). If the simulated effects of the SDIL are sustained over the life course, it is predicted that the cohort of children born today will experience a small (<1 percentage point) but significant reduction in health inequality.

Our finding of a 15.0 g/household/week (95% confidence interval: 10.3 to 19.7) reduction in sugar purchased in drinks in England is somewhat larger than the 8.0 g/household/week (2.4 to 13.6) reduction found by Rogers and colleagues [2] for the whole of Great Britain. The controlled interrupted time series analyses methods are identical between the 2 studies, although the data sets are slightly different. While our study of data from England included follow-up data to 19 months after SDIL implementation and the earlier study of data from Great Britain included follow-up data only to 12 months, reanalysis of the sugar reduction for Great Britain with 19 months of follow-up data (results not yet published) indicates that the effect has remained stable between 12 and 19 months. This suggests that the difference in results are not due to differences in follow-up time since SDIL implementation. It is possible that there are regional differences in impact of the SDIL. We included data from households in England only, due to differences in the way that deprivation is measured across the different countries of Great Britain. However, England constitutes around 85% of the population of Great Britain and would be expected to have the majority influence on the results. The differences in mean sugar reduction is perhaps most likely due to the interrupted time series approach; in particular, the way in which it generates counterfactuals that act as the baseline against which we measure effect size. Small deviations in the trend in the “before” period could result in quite large deviations in the counterfactual with extrapolation over longer and longer time periods. In our analyses, the “before” period ends with the SDIL announcement in March 2016 and then the counterfactual is extrapolated over more than 3 years. A small difference in the initial downwards trend in sugar purchasing (e.g., +/− 0.1 g/month) could result in a big difference in the counterfactual estimate of sugar purchasing by the end of the study in November 2019 (+/− 4.4 g sugar). Given that the initial trend is based on regression analysis over relatively few time points, this approach is potentially going to be sensitive to small fluctuations in the initial data set (such as reducing the data set from Great Britain to England only). This may also explain the slightly unusual patterns in the sugar reduction effect across IMD quintiles, i.e., large reductions in Q1 and Q2, small significant increase in Q3, nonsignificant change in Q4 and small reduction in Q5. A similar pattern was found in analyses of the SDIL and childhood obesity [55], where a reduction in population prevalence of obesity was found in Year 6 girls in the most deprived groups (IMD 1 and 2) and the least deprived group (IMD 5), but not in the intermediate deprivation groups (IMD 3 and 4). Other reasons for the pattern could include changing demographics of the population over the course of the study, which may have led to more noise, or perhaps differences in susceptibility to marketing or advertising. It is also important to remember that the Kantar data set includes only products brought into the home. It is possible that the proportion of in-home and out-of-home purchasing of soft drinks has been changing over time, and that this has varied by level of deprivation.

Our study suggests that the SDIL will have comparable or even larger simulated effects than other interventions in the UK for which health inequalities related to obesity and related health impacts have been evaluated. A modelling study of the NHS health checks program, a cardiovascular risk screening program for middle-aged adults in England, estimated that it would increase life expectancy by 4.4 days for adults in the most deprived IMD quintile [56]. This is considerably less than the additional 18 days for females and 31 days for males that our modelling predicts for the most deprived quintile, if the effects of the SDIL are sustained. It is likely that this difference is partly due to the effect size of the SDIL and partly due to its operation over the entire life course. Another modelling study that simulated removal of all unhealthy food advertising before 9 PM on UK television estimated that reductions in overweight and obesity would be 2 to 2.5 times higher for children in the lowest social grade, compared to children in the highest social grade [57]. Overall, that study estimated that the advertising restrictions might lead to 120,000 (95% UI 34,000 to 240,000) fewer children classified as overweight or obese in the UK. The uncertainty interval around this simulated effect is large owing to the necessary extrapolation of kilocalorie effects from small-scale experimental studies. Allowing for the smaller size of the population of England (approximately 0.865 of the UK population), the simulated effects of the TV advertising restrictions are comparable to our estimated reduction of 64,100 (95% uncertainty interval: 54,400 to 73,400) fewer children and adolescents classified as overweight or obese after implementation of the SDIL in England.

Our study of the SDIL in England adds to the small number of evaluations of the impact of SSB taxes across different socioeconomic groups. Like the SSB tax in Mexico [24,25], our study found larger impacts for the more deprived or lower socioeconomic groups. But this differs from the experience in Chile, where the SSB tax led to larger reductions in purchases for high socioeconomic groups [26,27]. Modelling studies that have explored socioeconomic differences of existing or hypothetical SSB taxes have also shown mixed results [58], while all predict beneficial health outcomes in the population overall, only 3 studies have predicted that the health effects would be progressive [5961], as we have found, while 4 studies have predicted similar or mixed outcomes across socioeconomic groups [41,6264].

A key strength of our study of the SDIL and health inequalities is that it combines medium-term and long-term modelling of health outcomes with an empirical evaluation of a real-world intervention. A number of previous studies have modelled socioeconomic differentials in health effects of hypothetical taxes targeting SSBs and have used economic models of demand to estimate how consumers would change purchasing behaviour for both targeted and non-targeted food and drinks [41,5964]. In contrast, a real-world evaluation provides evidence of effects regardless of the mechanisms of change, likely increasing internal validity and providing stronger evidence for policy makers [58]. For example, it is known that the SDIL had a substantial impact on reformulation of soft drinks [65], which is a mechanism that would not be accounted for in studies that estimate sugar purchases using economic models of demand alone.

However, our study still relies on a number of assumptions. For example, in evaluating the impact of the SDIL on sugar in purchased drinks using the controlled interrupted time series models, we assume that modelled trends in sugar purchasing up to the time of the SDIL announcement would have continued if the SDIL had not been announced or implemented. The data show that sugar purchased in drinks was already declining across all IMD quintiles before announcement of the SDIL in March 2016 (S2 Text), possibly due to raised awareness brought about by the focus on sugar reduction in the Childhood Obesity Plan. It is possible that these downward trends would not have continued at the same rate, particularly in the less deprived quintiles in which the mean purchase of sugar in drinks had already declined to relatively lower levels by the time of the SDIL announcement.

The Kantar data set that we used for the interrupted time series analyses is a database of products purchased and brought into the home; it does not provide information about the use or consumption of products by individuals within the household. Thus, there is uncertainty about how the changes in household purchasing of sugar in drinks are distributed among household members. In modelling the health implications from the changes in sugar attributed to the SDIL, we estimated an average per person impact on sugar intake from the average household size, within each IMD quintile, but it is likely that there will be additional variation in effects by age that we have not accounted for. Additionally, we assume that the reduction in sugar in purchased drinks translates directly into a reduction in sugar consumption. While there is some evidence to suggest that food purchases are a reasonable proxy for dietary intake of nutrients, such as sugar [34,35], there is still uncertainty around whether factors such as waste and out-of-home purchasing vary across deprivation quintiles. We also assume that there are no compensatory changes in energy expenditure (e.g., through changes in physical activity). However, we can be more confident that compensatory changes in energy intake have not occurred. Analyses of confectionery purchases over the time period of announcement and implementation of the SDIL found no evidence of compensatory changes in intake [2], which supports findings from other studies examining potential food substitution with SSB taxes [66,67]. Our purchasing data included all drink purchases that were brought into the home, but does not include drinks that were purchased and consumed outside of the home. It is estimated that 10% to 12% of expenditure on cold non-alcohol beverages in the UK is spent on out-of-home purchases [68], and it is possible this may affect some age groups more than others (e.g., teenager may be more likely to purchase drinks outside of the home). If the SDIL provoked a similar reduction in purchasing of these out-of-home drinks, then we will have underestimated the full effect of the levy—however, more work is needed to establish this.

Our modelling approach accounted for parametric uncertainty around key model parameters (drinks purchasing, sugar impact on dental caries/BMI, and dental caries/BMI impact on quality of life and mortality). However, all modelling studies are subject to structural uncertainty—that is, uncertainty about whether our modelling framework is an accurate representation of reality. Obesity is complex to model, particularly at the level of the individual. However, it is important to note that in this paper we are chiefly concerned with trends in BMI at the population level, where much of the individual-level complexity is cancelled out. This is illustrated by looking at trends in BMI distributions [69], which are smooth and predictable. This type of lifetable modelling has a long history of being used to model the long-term health effects of population changes in body weight [57,7077]. Our long-term models necessarily make assumptions about the long-term resilience of the effect of the SDIL, which has not yet been established. The uncertainty estimates around our long-term results do not reflect this. Finally, in the quality-adjustment of life expectancy and years of life lived, we rely on published estimates of utility values to reflect quality of life associated with having dental caries or obesity, and to reflect the average background quality of life at different ages, sex, and IMD quintiles. The development and use of measurement instruments, such as the EQ-5D is well-established in the adult population, but there is far less evidence relating to the experience of children and adolescents. In their systematic review of obesity-related utility values in children and adolescents, for example, Brown and colleagues [49] highlighted the dearth of relevant studies and the resulting high heterogeneity in meta-analysis results. While the uncertainty in child and adolescent utility values does not affect our modelled estimates of dental caries numbers, obesity prevalence, or life expectancy, our estimates of quality-adjusted life years and quality-adjusted life expectancy should be interpreted with more caution.

Our analyses show that the SDIL has had larger benefits for more deprived groups in England, and that this is likely to lead to small but significant reductions in health inequalities in the medium and long term. There are clear benefits from addressing health inequalities early in life; social gradients that develop in childhood can impact across the life course [78,79]. Recommendations to address health inequalities were made at the conclusion of the Marmot review [16] in 2010. But while there are notable examples of subsequent action at the local government level, commitment is lacking at the national level, and over 10 years on from the review, health inequalities have continued to widen [17]. Our study illustrates how the SDIL is likely to contribute to narrowing health inequalities in England.

The SDIL approach to fiscal beverage policy provides incentives for reformulation; there may be benefits from extending this approach to a wider array of products in the UK [80]. This could include sweetened milk-based drinks, which are currently excluded from the SDIL, or snack foods. While soft drinks are responsible for 10% of free sugar intake in 4 to 10 year olds and 23% in 11 to 18 year olds, sugar, preserves, and confectionery are responsible for a further 24% of intake in 4 to 10 year olds and a further 22% of intake in 11 to 18 year olds [7]. Modelling suggests that price increases in high sugar snacks might further reduce health inequalities in the UK [81]. There may be benefits in targeting non-core foods, such as confectionery, where untaxed (or subsidised) substitutes are available, to minimise any potential regressive effects of the policy. A tax on sugar was recently advocated in an independent report to inform the UK’s national food strategy [82]. Modelling estimates suggest it would have a beneficial effect in reducing sugar consumption overall in the UK population [83], but further work is needed to determine if it would also reduce health inequalities.

While our study shows that the SDIL is likely to be progressive in its simulated effects on health, it does not tell us anything about the financial impact on households. But work is ongoing to examine the socioeconomic effects of the SDIL in more detail, including evaluation of household economic impacts and effects of the SDIL on the wider UK economy. Our work here focussed on the health impacts of the current cohort of children and adolescents in the UK and on the simulated effect of the SDIL on health inequalities. Further ongoing modelling work will report on the health impact on adults, including disease-specific outcomes.

Supporting information

S1 Text. Interrupted time series analysis.

(DOCX)

pmed.1004371.s001.docx (19.6KB, docx)
S2 Text. Lifetable analysis data inputs.

(DOCX)

pmed.1004371.s002.docx (5.4MB, docx)
S3 Text. Additional results.

(DOCX)

pmed.1004371.s003.docx (511.1KB, docx)

Abbreviations

BMI

body mass index

IMD

index of multiple deprivation

QALY

quality-adjusted life year

SDIL

soft drinks industry levy

SII

slope index of inequality

SSB

sugar-sweetened beverage

Data Availability

The data that support the PRIMEtime model are freely available from the following sources: o Global Burden of Disease Project (https://vizhub.healthdata.org/gbd-results/) o Office for National Statistics (https://vizhub.healthdata.org/gbd-results/) o Health Survey for England (https://digital.nhs.uk/data-and-information/publications/statistical/health-survey-for-england) o Children’s Dental Health Survey 2013 (https://digital.nhs.uk/data-and-information/publications/statistical/children-s-dental-health-survey/child-dental-health-survey-2013-england-wales-and-northern-ireland) o Adult’s Dental Health Survey 2009 (https://digital.nhs.uk/data-and-information/publications/statistical/adult-dental-health-survey/adult-dental-health-survey-2009-summary-report-and-thematic-series) The interrupted time series analyses uses commercial data purchased from Kantar Fast Moving Consumer Goods Panel and cannot be shared without permission from the data owners. Data requests can be submitted to Kantar using the online contact us form found here: https://www.kantar.com/contact/hq-general-contact.

Funding Statement

This research is supported by a project grant from the NIHR Public Health Research Programme (NIHR PHR 16/130/01). PS is supported by the NIHR Oxford Health Biomedical Research Centre at Oxford (NIHR203316). OM is supported by a UKRI Future Leaders Fellowship (MR/T041226/1). MW and JMA are supported by an intramural programme grant within the MRC Epidemiology Unit (MC/UU/00006/7). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.HM Revenue & Customs. Soft Drinks Industry Levy: Detailed Information: UK Government. [cited 2021 Apr 7]. https://www.gov.uk/topic/business-tax/soft-drinks-industry-levy.
  • 2.Rogers NT, Pell D, Mytton OT, Penney TL, Briggs A, Cummins S, et al. Changes in soft drinks purchased by British households associated with the UK soft drinks industry levy: a controlled interrupted time series analysis. BMJ Open. 2023;13(12):e077059. doi: 10.1136/bmjopen-2023-077059 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Department of Health and Social Care. Childhood obesity: a plan for action. UK: Cabinet Office, Department of Health and Social Care, HM Treasury, and Prime Minister’s Office, 10 Downing Street. 2016.
  • 4.Public Health England. Sugar reduction: responding to the challenge. UK: Public Health England; 2014.
  • 5.Scientific Advisory Committee on Nutrition. Carbohydrates and Health. UK: Public Health England; 2015.
  • 6.Public Health England. Results of the National Diet and Nutrition Survey (NDNS) rolling programme for 2014 to 2015 and 2015 to 2016. UK: Public Health England and Food Standards Agency; 2018.
  • 7.Amoutzopoulos B, Steer T, Roberts C, Collins D, Page P. Free and added sugar consumption and adherence to guidelines: the UK National Diet and Nutrition Survey (2014/15–2015/16). Nutrients. 2020;12(2):393. doi: 10.3390/nu12020393 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Ebbeling CB, Feldman HA, Chomitz VR, Antonelli TA, Gortmaker SL, Osganian SK, et al. A randomized trial of sugar-sweetened beverages and adolescent body weight. N Engl J Med. 2012;367:1407–1416. doi: 10.1056/NEJMoa1203388 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.de Ruyter JC, Olthof MR, Seidell JC, Katan MB. A trial of sugar-free or sugar-sweetened beverages and body weight in children. N Engl J Med. 2012;367(15):1397–1406. doi: 10.1056/NEJMoa1203034 [DOI] [PubMed] [Google Scholar]
  • 10.Valenzuela MJ, Waterhouse B, Aggarwal VR, Bloor K, Doran T. Effect of sugar-sweetened beverages on oral health: A systematic review and meta-analysis. Eur J Public Health. 2021;31(1):122–129. doi: 10.1093/eurpub/ckaa147 [DOI] [PubMed] [Google Scholar]
  • 11.El-Sayed AM, Scarborough P, Galea S. Socioeconomic inequalities in childhood obesity in the United Kingdom: a systematic review of the literature. Obes Facts. 2012;5(5):671–692. doi: 10.1159/000343611 [DOI] [PubMed] [Google Scholar]
  • 12.Public Health England. National child measurement programme (NCMP): trends in child BMI UK: Public Health England; 2020. https://www.gov.uk/government/statistics/national-child-measurement-programme-ncmp-trends-in-child-bmi-between-2006-to-2007-and-2018-to-2019.
  • 13.Masood M, Mnatzaganian G, Baker SR. Inequalities in dental caries in children within the UK: Have there been changes over time? Community Dent Oral Epidemiol. 2019;47(1):71–77. [DOI] [PubMed] [Google Scholar]
  • 14.Ravaghi V, Hargreaves D, Morris A. Persistent socioeconomic inequality in child dental caries in England despite equal attendance. JDR Clin Trans Res. 2020;5(2):185–194. doi: 10.1177/2380084419872136 [DOI] [PubMed] [Google Scholar]
  • 15.Gray AM. Inequalities in health. The Black Report: a summary and comment. Int J Health Serv. 1982;12(3):349–380. doi: 10.2190/XXMM-JMQU-2A7Y-HX1E [DOI] [PubMed] [Google Scholar]
  • 16.Marmot M, Allen J, Goldblatt P, Boyce T, McNeish D, Grady M, et al. Fair society, healthy lives: the Marmot review. London: 2010.
  • 17.Institute of Health Equity. Health equity in England: the Marmot review 10 years on. London: Institute of Health Equity; 2020. [Google Scholar]
  • 18.Health state life expectancies by national deprivation deciles, England: 2017 to 2019 UK: Office for National Statistics. 2021 [cited 2021 May 23]. https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/healthinequalities/bulletins/healthstatelifeexpectanciesbyindexofmultipledeprivationimd/2017to2019.
  • 19.Bennett JE, Pearson-Stuttard J, Kontis V, Capewell S, Wolfe I, Ezzati M. Contributions of diseases and injuries to widening life expectancy inequalities in England from 2001 to 2016: a population-based analysis of vital registration data. Lancet Public Health. 2018;3(12):e586–e597. doi: 10.1016/S2468-2667(18)30214-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Rashid T, Bennett JE, Paciorek CJ, Doyle Y, Pearson-Stuttard J, Flaxman S, et al. Life expectancy and risk of death in 6791 communities in England from 2002 to 2019: high-resolution spatiotemporal analysis of civil registration data. Lancet Public Health. 2021;6(11):e805–e816. doi: 10.1016/S2468-2667(21)00205-X [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Raleigh V. What is happening to life expectancy in England. The King’s Fund. 2021.
  • 22.Backholer K, Sarink D, Beauchamp A, Keating C, Loh V, Ball K, et al. The impact of a tax on sugar-sweetened beverages according to socio-economic position: a systematic review of the evidence. Public Health Nutr. 2016;19(17):3070–3084. doi: 10.1017/S136898001600104X [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Global Food Research Program. Sugary drink taxes around the world. University of North Carolina at Chapel Hill; 2022 [cited 2022 May 30]. https://www.globalfoodresearchprogram.org/resources/maps/.
  • 24.Colchero MA, Molina M, Guerrero-López CM. After Mexico implemented a tax, purchases of sugar-sweetened beverages decreased and water increased: difference by place of residence, household composition, and income level. J Nutr. 2017;147(8):1552–1557. doi: 10.3945/jn.117.251892 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Colchero MA, Rivera-Dommarco J, Popkin BM, Ng SW. In Mexico, evidence of sustained consumer response two years after implementing a sugar-sweetened beverage tax. Health Aff (Millwood). 2017;36(3):564–571. doi: 10.1377/hlthaff.2016.1231 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Nakamura R, Mirelman AJ, Cuadrado C, Silva-Illanes N, Dunstan J, Suhrcke M. Evaluating the 2014 sugar-sweetened beverage tax in Chile: an observational study in urban areas. PLoS Med. 2018;15(7):e1002596. doi: 10.1371/journal.pmed.1002596 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Caro JC, Corvalán C, Reyes M, Silva A, Popkin B, Taillie LS. Chile’s 2014 sugar-sweetened beverage tax and changes in prices and purchases of sugar-sweetened beverages: An observational study in an urban environment. PLoS Med. 2018;15(7):e1002597. doi: 10.1371/journal.pmed.1002597 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Smith T, Noble M, Noble S, Wright G, McLennan D, Plunkett E. English indices of deprivation 2015: technical report. UK: Department for Communities and Local Government; 2015.
  • 29.Lopez Bernal J, Cummins S, Gasparrini A. The use of controls in interrupted time series studies of public health interventions. Int J Epidemiol. 2018;47(6):2082–2093. doi: 10.1093/ije/dyy135 [DOI] [PubMed] [Google Scholar]
  • 30.Bernal JL, Cummins S, Gasparrini A. Interrupted time series regression for the evaluation of public health interventions: a tutorial. Int J Epidemiol. 2017;46(1):348–355. doi: 10.1093/ije/dyw098 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Oehlert GW. A note on the delta method. Am Stat. 1992;46(1):27–29. [Google Scholar]
  • 32.Office for National Statistics. Deaths and Populations by sex, age and IMD decile, England & Wales, 2001–2015 2017 [cited 2020 June 8]. https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/adhocs/006518deathsandpopulationsbyindexofmultipledeprivationimddecileenglandandwales2001to2015.
  • 33.Office for National Statistics. 2016-based National Population Projections 2017 [cited 2020 Sep 1]. https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationprojections/datasets/z3zippedpopulationprojectionsdatafilesengland.
  • 34.Appelhans BM, French SA, Tangney CC, Powell LM, Wang Y. To what extent do food purchases reflect shoppers’ diet quality and nutrient intake? Int J Behav Nutr Phys Act. 2017;14(1):46. doi: 10.1186/s12966-017-0502-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Eyles H, Jiang Y, Mhurchu CN. Use of household supermarket sales data to estimate nutrient intakes: a comparison with repeat 24-hour dietary recalls. J Am Diet Assoc. 2010;110(1):106–110. doi: 10.1016/j.jada.2009.10.005 [DOI] [PubMed] [Google Scholar]
  • 36.Number of households by household size and age of household reference person (HRP), English regions and UK constituent countries, 2019 UK: Office for National Statistics. 2019 [cited 2019 June 22]. https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/families/adhocs/11520numberofhouseholdsbyhouseholdsizeandageofhouseholdreferencepersonhrpenglishregionsandukconstituentcountries2019.
  • 37.FAO. Food energy—methods of analysis and conversion factors. Rome: Food and Agriculture Organization of the United Nations; 2003.
  • 38.Hall KD, Butte NF, Swinburn BA, Chow CC. Dynamics of childhood growth and obesity: development and validation of a quantitative mathematical model. Lancet Diabetes Endocrinol. 2013;1(2):97–105. doi: 10.1016/s2213-8587(13)70051-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Hall KD, Sacks G, Chandramohan D, Chow CC, Wang YC, Gortmaker SL, et al. Quantification of the effect of energy imbalance on bodyweight. Lancet. 2011;378(9793):826–37. doi: 10.1016/S0140-6736(11)60812-X [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Maersk M, Belza A, Holst J, Fenger-Grøn M, Pedersen S, Astrup A, et al. Satiety scores and satiety hormone response after sucrose-sweetened soft drink compared with isocaloric semi-skimmed milk and with non-caloric soft drink: a controlled trial. Eur J Clin Nutr. 2012;66(4):523–529. doi: 10.1038/ejcn.2011.223 [DOI] [PubMed] [Google Scholar]
  • 41.Briggs AD, Mytton OT, Kehlbacher A, Tiffin R, Rayner M, Scarborough P. Overall and income specific effect on prevalence of overweight and obesity of 20% sugar sweetened drink tax in UK: econometric and comparative risk assessment modelling study. BMJ. 2013;347. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Office for National Statistics. Health Survey for England. England: NHS Digital; 2015 [cited 2020 Sep 14]. https://digital.nhs.uk/data-and-information/publications/statistical/health-survey-for-england.
  • 43.Cole TJ, Lobstein T. Extended international (IOTF) body mass index cut-offs for thinness, overweight and obesity. Pediatr Obes. 2012;7(4):284–294. doi: 10.1111/j.2047-6310.2012.00064.x [DOI] [PubMed] [Google Scholar]
  • 44.Bernabé E, Vehkalahti MM, Sheiham A, Lundqvist A, Suominen AL. The shape of the dose-response relationship between sugars and caries in adults. J Dent Res. 2016;95(2):167–172. doi: 10.1177/0022034515616572 [DOI] [PubMed] [Google Scholar]
  • 45.Office for National Statistics Social Survey Division. Adult Dental Health Survey, 2009. UK Data Service; 2012.
  • 46.Office for National Statistics Social Survey Division. Children’s Dental Health Survey, 2013. UK Data Service; 2015.
  • 47.Di Angelantonio E, Bhupathiraju SN, Wormser D, Gao P, Kaptoge S, de Gonzalez AB, et al. Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents. Lancet. 2016;388(10046):776–786. doi: 10.1016/S0140-6736(16)30175-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Love-Koh J, Asaria M, Cookson R, Griffin S. The social distribution of health: estimating quality-adjusted life expectancy in England. Value Health. 2015;18(5):655–662. doi: 10.1016/j.jval.2015.03.1784 [DOI] [PubMed] [Google Scholar]
  • 49.Brown V, Tan E, Hayes A, Petrou S, Moodie ML. Utility values for childhood obesity interventions: a systematic review and meta-analysis of the evidence for use in economic evaluation. Obes Rev. 2018;19(7):905–916. [DOI] [PubMed] [Google Scholar]
  • 50.Maheswaran H, Petrou S, Rees K, Stranges S. Estimating EQ-5D utility values for major health behavioural risk factors in England. J Epidemiol Community Health. 2013;67(2):172–180. doi: 10.1136/jech-2012-201019 [DOI] [PubMed] [Google Scholar]
  • 51.Sullivan PW, Slejko JF, Sculpher MJ, Ghushchyan V. Catalogue of EQ-5D scores for the United Kingdom. Med Decis Making. 2011;31(6):800–804. doi: 10.1177/0272989X11401031 [DOI] [PubMed] [Google Scholar]
  • 52.Pamuk ER. Social Class Inequality in Mortality From 1921 to 1972 in England and Wales. Popul Stud. 1985;39(1):17–31. doi: 10.1080/0032472031000141256 [DOI] [PubMed] [Google Scholar]
  • 53.NHS Group. NHS Outcomes Framework: Indicators for health inequalities assessment. UK: Department of Health; 2015.
  • 54.Khang Y-H, Lim D, Bahk J, Kim I, Kang H-Y, Chang Y, et al. A publicly well-accepted measure versus an academically desirable measure of health inequality: cross-sectional comparison of the difference between income quintiles with the slope index of inequality. BMJ Open. 2019;9(6):e028687. doi: 10.1136/bmjopen-2018-028687 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Rogers NT, Cummins S, Forde H, Jones CP, Mytton O, Rutter H, et al. Associations between trajectories of obesity prevalence in English primary school children and the UK soft drinks industry levy: An interrupted time series analysis of surveillance data. PLoS Med. 2023;20(1):e1004160. doi: 10.1371/journal.pmed.1004160 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Mytton OT, Jackson C, Steinacher A, Goodman A, Langenberg C, Griffin S, et al. The current and potential health benefits of the National Health Service Health Check cardiovascular disease prevention programme in England: a microsimulation study. PLoS Med. 2018;15(3):e1002517. doi: 10.1371/journal.pmed.1002517 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Mytton OT, Boyland E, Adams J, Collins B, O’Connell M, Russell SJ, et al. The potential health impact of restricting less-healthy food and beverage advertising on UK television between 05.30 and 21.00 hours: A modelling study. PLoS Med. 2020;17(10):e1003212. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Teng AM, Jones AC, Mizdrak A, Signal L, Genç M, Wilson N. Impact of sugar-sweetened beverage taxes on purchases and dietary intake: Systematic review and meta-analysis. Obes Rev. 2019;20(9):1187–1204. doi: 10.1111/obr.12868 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Lal A, Mantilla-Herrera AM, Veerman L, Backholer K, Sacks G, Moodie M, et al. Modelled health benefits of a sugar-sweetened beverage tax across different socioeconomic groups in Australia: A cost-effectiveness and equity analysis. PLoS Med. 2017;14(6):e1002326. doi: 10.1371/journal.pmed.1002326 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Sharma A, Hauck K, Hollingsworth B, Siciliani L. The effects of taxing sugar-sweetened beverages across different income groups. Health Econ. 2014;23(9):1159–1184. doi: 10.1002/hec.3070 [DOI] [PubMed] [Google Scholar]
  • 61.Zhen C, Finkelstein EA, Nonnemaker JM, Karns SA, Todd JE. Predicting the effects of sugar-sweetened beverage taxes on food and beverage demand in a large demand system. Am J Agric Econ. 2014;96(1):1–25. doi: 10.1093/ajae/aat049 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.Briggs AD, Mytton OT, Madden D, O’Shea D, Rayner M, Scarborough P. The potential impact on obesity of a 10% tax on sugar-sweetened beverages in Ireland, an effect assessment modelling study. BMC Public Health. 2013;13(1):1–9. doi: 10.1186/1471-2458-13-860 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Finkelstein EA, Zhen C, Nonnemaker J, Todd JE. Impact of targeted beverage taxes on higher-and lower-income households. Arch Intern Med. 2010;170(22):2028–2034. doi: 10.1001/archinternmed.2010.449 [DOI] [PubMed] [Google Scholar]
  • 64.Lin B-H, Smith TA, Lee J-Y, Hall KD. Measuring weight outcomes for obesity intervention strategies: the case of a sugar-sweetened beverage tax. Econ Hum Biol. 2011;9(4):329–341. doi: 10.1016/j.ehb.2011.08.007 [DOI] [PubMed] [Google Scholar]
  • 65.Scarborough P, Adhikari V, Harrington RA, Elhussein A, Briggs A, Rayner M, et al. Impact of the announcement and implementation of the UK Soft Drinks Industry Levy on sugar content, price, product size and number of available soft drinks in the UK, 2015–19: A controlled interrupted time series analysis. PLoS Med. 2020;17(2):e1003025. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66.Finkelstein EA, Zhen C, Bilger M, Nonnemaker J, Farooqui AM, Todd JE. Implications of a sugar-sweetened beverage (SSB) tax when substitutions to non-beverage items are considered. J Health Econ. 2013;32(1):219–239. doi: 10.1016/j.jhealeco.2012.10.005 [DOI] [PubMed] [Google Scholar]
  • 67.Waterlander WE, Mhurchu CN, Steenhuis IH. Effects of a price increase on purchases of sugar sweetened beverages. Results from a randomized controlled trial. Appetite. 2014;78:32–39. doi: 10.1016/j.appet.2014.03.012 [DOI] [PubMed] [Google Scholar]
  • 68.Cornelsen L, Berger N, Cummins S, Smith RD. Socio-economic patterning of expenditures on ‘out-of-home’food and non-alcoholic beverages by product and place of purchase in Britain. Soc Sci Med. 2019;235:112361. doi: 10.1016/j.socscimed.2019.112361 [DOI] [PubMed] [Google Scholar]
  • 69.Cobiac LJ, Scarborough P. Modelling future trajectories of obesity and body mass index in England. PLoS ONE. 2021;16(6):e0252072. doi: 10.1371/journal.pone.0252072 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 70.Forster M, Veerman JL, Barendregt JJ, Vos T. Cost-effectiveness of diet and exercise interventions to reduce overweight and obesity. Int J Obes (Lond). 2011. doi: 10.1038/ijo.2010.246 [DOI] [PubMed] [Google Scholar]
  • 71.Cleghorn C, Jones A, Freeman L, Wilson N. Updated Cost-effectiveness Modelling of a Behavioural Weight Loss Intervention Involving a Primary Care Provider. New Zealand: University of Otago; 2020. [Google Scholar]
  • 72.Cleghorn C, Wilson N, Nair N, Kvizhinadze G, Nghiem N, McLeod M, et al. Health benefits and cost-effectiveness from promoting smartphone apps for weight loss: multistate life table modeling. JMIR Mhealth Uhealth. 2019;7(1):e11118. doi: 10.2196/11118 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 73.Ekwaru JP, Ohinmaa A, Tran BX, Setayeshgar S, Johnson JA, Veugelers PJ. Cost-effectiveness of a school-based health promotion program in Canada: A life-course modeling approach. PLoS ONE. 2017;12(5):e0177848. doi: 10.1371/journal.pone.0177848 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 74.Veerman J, Barendregt J, Forster M, Vos T. Cost-Effectiveness of Pharmacotherapy to Reduce Obesity. PLoS ONE. 2011;6(10):e26051. doi: 10.1371/journal.pone.0026051 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 75.Haby M, Vos T, Carter R, Moodie M, Markwick A, Magnus A, et al. A new approach to assessing the health benefit from obesity interventions in children and adolescents: the Assessing Cost-Effectiveness in obesity project. Int J Obes (Lond). 2006;30:1463–1475. doi: 10.1038/sj.ijo.0803469 [DOI] [PubMed] [Google Scholar]
  • 76.Brown V, Ananthapavan J, Sonntag D, Tan EJ, Hayes A, Moodie M. The potential for long-term cost-effectiveness of obesity prevention interventions in the early years of life. Pediatr Obes. 2019;14(8):e12517. doi: 10.1111/ijpo.12517 [DOI] [PubMed] [Google Scholar]
  • 77.Gortmaker SL, Long MW, Resch SC, Ward ZJ, Cradock AL, Barrett JL, et al. Cost effectiveness of childhood obesity interventions: evidence and methods for CHOICES. Am J Prev Med. 2015;49(1):102–111. doi: 10.1016/j.amepre.2015.03.032 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 78.Pillas D, Marmot M, Naicker K, Goldblatt P, Morrison J, Pikhart H. Social inequalities in early childhood health and development: a European-wide systematic review. Pediatr Res. 2014;76(5):418–424. doi: 10.1038/pr.2014.122 [DOI] [PubMed] [Google Scholar]
  • 79.Poulton R, Caspi A, Milne BJ, Thomson WM, Taylor A, Sears MR, et al. Association between children’s experience of socioeconomic disadvantage and adult health: a life-course study. Lancet. 2002;360(9346):1640–1645. doi: 10.1016/S0140-6736(02)11602-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 80.Smith RD, Cornelsen L, Quirmbach D, Jebb SA, Marteau TM. Are sweet snacks more sensitive to price increases than sugar-sweetened beverages: analysis of British food purchase data. BMJ Open. 2018;8(4):e019788. doi: 10.1136/bmjopen-2017-019788 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 81.Scheelbeek PF, Cornelsen L, Marteau TM, Jebb SA, Smith RD. Potential impact on prevalence of obesity in the UK of a 20% price increase in high sugar snacks: modelling study. BMJ. 2019:366. doi: 10.1136/bmj.l4786 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 82.National Food Strategy team. National Food Strategy independent review: the plan. London: National Food Strategy; 2021. [Google Scholar]
  • 83.Griffith R, Jenneson V, James J, Taylor A. The impact of a tax on added sugar and salt. London: Institute for Fiscal Studies; 2021. [Google Scholar]

Decision Letter 0

Philippa C Dodd

13 Oct 2023

Dear Dr Scarborough,

Thank you for submitting your manuscript entitled "Impact of the UK Soft Drinks Industry Levy on health and health inequalities in children and adolescents in England: an interrupted time series analysis and population health modelling study" for consideration by PLOS Medicine.

Your manuscript has now been evaluated by the PLOS Medicine editorial staff and I am writing to let you know that we would like to send your submission out for external peer review.

However, before we can send your manuscript to reviewers, we need you to complete your submission by providing the metadata that is required for full assessment. To this end, please login to Editorial Manager where you will find the paper in the 'Submissions Needing Revisions' folder on your homepage. Please click 'Revise Submission' from the Action Links and complete all additional questions in the submission questionnaire.

Please re-submit your manuscript within two working days, i.e. by Oct 17 2023 11:59PM.

Login to Editorial Manager here: https://www.editorialmanager.com/pmedicine

Once your full submission is complete, your paper will undergo a series of checks in preparation for peer review. Once your manuscript has passed all checks it will be sent out for review.

Feel free to email us at plosmedicine@plos.org if you have any queries relating to your submission.

Sincerely,

Philippa Dodd, MBBS MRCP PhD

PLOS Medicine

Decision Letter 1

Philippa C Dodd

23 Nov 2023

Dear Dr. Scarborough,

Thank you very much for submitting your manuscript "Impact of the UK Soft Drinks Industry Levy on health and health inequalities in children and adolescents in England: an interrupted time series analysis and population health modelling study" (PMEDICINE-D-23-02980R1) for consideration at PLOS Medicine.

Your paper was evaluated by a senior editor and discussed among all the editors here. It was also discussed with an academic editor with relevant expertise, and sent to independent reviewers, including a statistical reviewer. The reviews are appended at the bottom of this email and any accompanying reviewer attachments can be seen via the link below:

[LINK]

In light of these reviews, I am pleased to tell you that we would like to consider a revised version that addresses the reviewers' and editors' comments. Obviously we cannot make any decision about publication until we have seen the revised manuscript and your response, and we plan to seek re-review by one or more of the reviewers.

In revising the manuscript for further consideration, your revisions should address the specific points made by each reviewer and the editors. Please also check the guidelines for revised papers at http://journals.plos.org/plosmedicine/s/revising-your-manuscript for any that apply to your paper. In your rebuttal letter you should indicate your response to the reviewers' and editors' comments, the changes you have made in the manuscript, and include either an excerpt of the revised text or the location (eg: page and line number) where each change can be found. Please submit a clean version of the paper as the main article file; a version with changes marked should be uploaded as a marked up manuscript.

In addition, we request that you upload any figures associated with your paper as individual TIF or EPS files with 300dpi resolution at resubmission; please read our figure guidelines for more information on our requirements: http://journals.plos.org/plosmedicine/s/figures. While revising your submission, please upload your figure files to the PACE digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at PLOSMedicine@plos.org.

We expect to receive your revised manuscript by Dec 14 2023 11:59PM. Please email us (plosmedicine@plos.org) if you have any questions or concerns.

***Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.***

We ask every co-author listed on the manuscript to fill in a contributing author statement, making sure to declare all competing interests. If any of the co-authors have not filled in the statement, we will remind them to do so when the paper is revised. If all statements are not completed in a timely fashion this could hold up the re-review process. If new competing interests are declared later in the revision process, this may also hold up the submission. Should there be a problem getting one of your co-authors to fill in a statement we will be in contact. YOU MUST NOT ADD OR REMOVE AUTHORS UNLESS YOU HAVE ALERTED THE EDITOR HANDLING THE MANUSCRIPT TO THE CHANGE AND THEY SPECIFICALLY HAVE AGREED TO IT. You can see our competing interests policy here: http://journals.plos.org/plosmedicine/s/competing-interests.

Please use the following link to submit the revised manuscript:

https://www.editorialmanager.com/pmedicine/

Your article can be found in the "Submissions Needing Revision" folder.

To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols

Please ensure that the paper adheres to the PLOS Data Availability Policy (see http://journals.plos.org/plosmedicine/s/data-availability), which requires that all data underlying the study's findings be provided in a repository or as Supporting Information. For data residing with a third party, authors are required to provide instructions with contact information for obtaining the data. PLOS journals do not allow statements supported by "data not shown" or "unpublished results." For such statements, authors must provide supporting data or cite public sources that include it.

We look forward to receiving your revised manuscript.

Best wishes,

Pippa

Philippa Dodd, MBBS MRCP PhD

PLOS Medicine

plosmedicine.org

pdodd@plos.org

-----------------------------------------------------------

COMMENTS FROM THE ACADEMIC EDITOR

Some of the queries point out fairly serious error, e.g using areal data to ascribe to each household Socio-economic status. I think this calls for a major revision. Some of the comments are not minor. If they address all the comments, we can then make a decision.

COMMENTS FROM THE EDITORS

GENERAL

Please respond to all editor and reviewer comments detailed below in full.

We understand the need to update the ITSA and to stratify by additional parameters to answer the specific question posed here. We agree with the statistical reviewer (please see below) that from a novelty perspective, it would be helpful to understand the rationale for the ITSA analysis destined for the BMJOpen as well as that presented here. Was the former to set a precedent for the (slightly updated) methodology used here, for example? Please provide details and please incorporate your response into the manuscript as necessary.

DATA AVAILABILITY STATEMENT

Thank you for including a statement pertaining to your data availability. The Data Availability Statement (DAS) requires revision. For each data source used in your study:

a) If the data are freely or publicly available, note this and state the location of the data: within the paper, in Supporting Information files, or in a public repository (include the DOI or accession number).

b) If the data are owned by a third party but freely available upon request, please note this and state the owner of the data set and contact information for data requests (web or email address). Note that a study author cannot be the contact person for the data.

c) If the data are not freely available, please describe briefly the ethical, legal, or contractual restriction that prevents you from sharing it. Please also include an appropriate contact (web or email address) for inquiries (again, this cannot be a study author).

We think that point c) would be most applicable here.

COMPETING INTERESTS

All authors must declare their relevant competing interests per the PLOS policy, which can be seen here:

https://journals.plos.org/plosmedicine/s/competing-interests

For authors with ties to industry, please indicate whether any of the interests has a financial stake in the results of the current study.

Please add this statement to the manuscript's Competing Interests: "JA is an Academic Editor on PLOS Medicine's editorial board."

ETHICS STATEMENT

As your study utilizes human participant data, we think an ethics statement would be appropriate.

ABSTRACT

Thank you for formatting your abstract according to PLOS Medicine’s style.

Abstract methods and findings:

Please include the study design, population and setting, number of participants, years during which the study took place, length of follow up, and please explicitly state the main outcome measures.

Please provide (brief) details of the databases used to leverage your data.

Please quantify the main results with 95% CIs (or UIs in this case) and p values. When reporting p values please report as p<0.001 and where higher the exact p value as p=0.002, for example. If not reporting p values, for the purpose of transparent data reporting please clearly state the reasons why not.

Please include any important dependent variables that are adjusted for in the analyses.

In the last sentence of the Abstract Methods and Findings section, please describe the main limitation(s) of the study's methodology.

Abstract Conclusions:

Please address the study implications without overreaching what can be concluded from the data; the phrase "In this study, we observed ..." may be useful.

Please interpret the study based on the results presented in the abstract, emphasizing what is new without overstating your conclusions.

Please avoid vague statements such as "these results have major implications for policy/clinical care". Mention only specific implications substantiated by the results.

Please avoid assertions of primacy ("We report for the first time....")

Line 49 – suggest ‘could’ instead of ‘will’.

AUTHOR SUMMARY

At this stage, we ask that you include a short, non-technical Author Summary of your research to make findings accessible to a wide audience that includes both scientists and non-scientists. The authors summary should consist of 2-3 succinct bullet points under each of the following headings:

• Why Was This Study Done? Authors should reflect on what was known about the topic before the research was published and why the research was needed.

• What Did the Researchers Do and Find? Authors should briefly describe the study design that was used and the study’s major findings. Do include the headline numbers from the study, such as the sample size and key findings.

• What Do These Findings Mean? Authors should reflect on the new knowledge generated by the research and the implications for practice, research, policy, or public health. Authors should also consider how the interpretation of the study’s findings may be affected by the study limitations. In the final bullet point of ‘What Do These Findings Mean?’, please describe the main limitations of the study in non-technical language.

The Author Summary should immediately follow the Abstract in your revised manuscript. This text is subject to editorial change and should be distinct from the scientific abstract. Please see our author guidelines for more information: https://journals.plos.org/plosmedicine/s/revising-your-manuscript#loc-author-summary

METHODS and RESULTS

Of all authors who submit modelling studies we ask that the following points are included in the main manuscript.

Please review the list below, derived from Geoffrey P Garnett, Simon Cousens, Timothy B Hallett, Richard Steketee, Neff Walker. Mathematical models in the evaluation of health programmes. (2011) Lancet DOI:10.1016/S0140-6736(10)61505-X and ensure that each item is included:

* Please provide a diagram that shows the model structure, including how the disease natural history is represented, the process and determinants of disease acquisition, and how the putative intervention could affect the system.

*Please provide a complete list of model parameters, including clear and precise descriptions of [the meaning of each parameter, together with the values or ranges for each, with justification or the primary source cited, and important caveats about the use of these values noted].

*Please provide a clear statement about how the model was fitted to the data [including goodness-of-fit measure, the numerical algorithm used, which parameter varied, constraints imposed on parameter values, and starting conditions].

*For uncertainty analyses, please state the sources of uncertainties quantified and not quantified [can include parameter, data, and model structure].

*Please provide sensitivity analyses to identify which parameter values are most important in the model. Uncertainty estimates seek to derive a range of credible results on the basis of an exploration of the range of reasonable parameter values. The choice of method should be presented and justified.

*Please discuss the scientific rationale for this choice of model structure and identify points where this choice could influence conclusions drawn. Please also describe the strength of the scientific basis underlying the key model assumptions.

Line 117 – should ‘MD’ be ‘IMD’ at the end of this line?

Please also see reviewer comments (below) regarding additional details required in respect of your methodology, which we agree with.

TABLES

Throughout please ensure that all tables are affiliated to an appropriate title and caption which clearly describes their content without the need to refer to the text.

Throughout, please ensure that all abbreviations including those used for statistical reporting are clearly defined for the reader.

Throughout, please clearly define the numerical values within the tables including those within brackets.

Throughout please indicate whether your analyses are adjusted (or not) and in the event that adjusted analyses are presented please detail the factors adjusted for (in an appropriate footnote/caption) and to help facilitate transparent data reporting, please also present the unadjusted analyses for comparison.

Throughout tables could be presented a little more accessibly and informatively for the reader. For example, when referring to means there are no units of measurement but some refer to weight, others to total number. This could be included in the columns headers for example, ‘mean sugar (g)’ presumably?

Suggest separating upper and lower CI bounds with commas to conserve space and prevent data being split across rows.

PLOS Medicine requires that where 95% CIs are reported, p values are also reported, please include and report as >0/001 and where higher the exact p value as 0.002, for example. If not reporting p values, for the purpose of transparent data reporting, please clearly state the reasons why not.

FIGURES

Throughout please cite figures (and tables) as outlined here https://journals.plos.org/plosmedicine/s/figures#loc-how-to-submit-figures-and-captions

Throughout (including the supporting information) please consider avoiding the sue of green and/or red so as to make your figures more accessible to those with color blindness.

Please ensure that all figures are affiliated to an appropriate title and caption that clearly describes the figure content without the need to refer to the text. Please ensure that any abbreviations including those used for statistical reporting are clearly defined for the reader.

Figure 2 – please include a caption. Please clearly state the meaning of the different colour shading. Please clearly define the meaning of the dots and the lines for the reader.

DISCUSSION

Please remove all sub-headings form the discussion such that it reads as continuous prose and please ensure that you organize the Discussion as follows: a short, clear summary of the article's findings; what the study adds to existing research and where and why the results may differ from previous research; strengths and limitations of the study; implications and next steps for research, clinical practice, and/or public policy; one-paragraph conclusion.

Please remove the financial disclosure and competing interests statement from the end of the discussion and include only in the manuscript submission form when you re-submit your manuscript. In the event of publication, this information will be compiled as metadata.

REFERENCES

For in text reference callouts please remove the spaces between different citations, for example line 67 should read ‘[3,4]’.

In the bibliography please ensure that you list up to but no more than 6 author names followed by et al.

For all web references please ensure you include an, ‘Accessed [date].’

Journal name abbreviations should be those listed in the National Center for Biotechnology Information (NCBI) databases.

SUPPORTING INFORMATION

Please ensure that you provide titles and legends for each individual table and figure in the Supporting Information which follow the guidance detailed above for the main manuscript.

In the published article, supporting information files are accessed only through a hyperlink attached to the captions. For this reason, you must list captions at the end of your manuscript file. You may include a caption within the supporting information file itself, as long as that caption is also provided in the manuscript file. Do not submit a separate caption file.

Please cite your Supporting Information as outlined here: https://journals.plos.org/plosmedicine/s/supporting-information

For in-text reference callouts please place citations in square parentheses separate by commas. For example, [1,3,6] or [1-3]. Please check and amend throughout all sub-sections of the manuscript and supporting files.

Please ensure that other referencing follows the format as detailed above for the main manuscript.

As for the main manuscript where reporting 95% CIs please also report p values as detailed above, if not please clearly state the reasons why not.

COMMENTS FROM THE REVIEWERS:

Reviewer #1: The paper models the potential on BMI and dental caries that occurred due to small reductions in sugar from beverages in UK households following a levy. The initial findings are promising that the intervention will effectively achieve increases reductions in both BMI and dental carries. While there are limitations to the methodology in that real dietary intake was not measured, the authors have described these in the limitations section. The analyses does not measure the impact on purchases not brought into the home, as sugary drinks are often consumed outside of the home, the authors may with to comment on this, particularly in relation to teenagers given the high intake of sugar in this age group.

Reviewer #2: Overview

This paper uses interrupted time series analyses and lifetable modelling to evaluate the effects of the UK soft drink industry levy on changes in sugar consumption, BMI, dental caries and QALYs in children and adolescents. This is an important topic, and the authors provide strong justification for their study. The paper is interesting, well written and thorough. I have made some minor comments and suggestions.

Comments

Introduction: Says that drinking with <0.5% ABV are exempt, I think this should be >1.2% ABV.

Results: I might have missed them, but I cannot see the full time series model specification and results in the main document or supplementary materials. It would be helpful to include these.

Discussion: This is excellent, and clearly explains every key limitation of the study that I noted from the methods.

Typo: MD line 117.

Note for editor: Thank you for the opportunity to review this paper. I would just like to note that I was unable to review the lifetable model in detail as I am not familiar with these methods. To the best of my knowledge, the methods appear robust.

Reviewer #3: Thank you to the authors for submitting this ambitious paper on a clearly very important topic - I enjoyed reading it. Although very well written, my overall opinion is that the paper is trying to do too much. As a consequence of this, several parts of the paper require far more explanation and detail. I also have concerns about some of the methods used and the similarity to another paper by most of the same authors. I feel as though the paper does have the potential for publication in this journal, however in my opinion a number of relatively substantive edits are needed.

My comments are organised in the order in which they appear in the manuscript, and I have noted whether they are 'major' or 'minor'.

Line 62: Reference to the Rogers et al unpublished paper. Do the authors expect this paper to be published imminently? (Minor)

Lines 81 - 83: This sentence explaining the results from the 2016 systematic review is a bit confusing. It implies that the studies included in the review had one of two (quite distinct) outcomes. I would like another sentence or two explaining the mechanisms behind these findings from the authors (Minor)

Lines 100 - 103: From reading this, it seems as though the only difference between ITS analysis in the Rogers et al unpublished study and this present study is the fact that you stratified by IMD and used Great Britain rather than England. These analyses are very similar, and to me could have quite easily been sensitivity analysis in the Roger et al unpublished study. I'm not sure these two very similar analyses can be justified as two separate papers (Major)

Lines 114 - 115: I'm not 100% convinced by the choice of control - has this been used in any other studies aside from the Rogers et al unpublished study? Are there any other alternative choices of control that could have been used? (Minor)

Lines 117 - 188: The Kantar dataset needs to be explained in a lot more detail (Major)

Lines 117 - 188: The levels of missing data need to be stated in order to get an idea of the extent of the issue (Major)

Line 130: I'm a bit confused by the weights. Could you please elaborate on exactly how they were used?

Line 139: Maybe it's my memory failing me, but I don't recall any widespread changes to consumer behaviour in December 2019 due to Britain's exit from the EU. It's not a big issue because COVID came soon after and this is clear justification for your cut-off point, but it seems a bit odd to me (Minor)

Line 147: I understand your use of the AIC to choose the optimal model, but I would like a bit more explanation regarding the number and type of different models you used when selecting your model.

Lines 157 - 166: I'm really not convinced by the life table modelling approach. Obesity (especially child/adolescent obesity) is a particularly difficult clinical area to model, with lifetime state transition models commonly used. I think there needs to be far more justification about why this highly simplified model structure is appropraite for this complex issue (Major)

Figure 1: I'm confused about how exactly you measured the impact of both BMI and Dental Caries on Quality of Life. Did you about for the fact that there may be an interactive effect? (Minor)

Lines 202 - 203: I appreciate the use of the EQ-5D to measure utility, however I think the authors need to state up front that these utility weights are based on a sample of adults rather than children. Although the EQ-5D-Y has been developed, there are no current population norms for either the 3L or 5L version, let alone utility scores by age, sex and IMD quintile (Major)

Line 203: I think it could be worth noting that the health state utilities gathered from reference number 49 and 50 are pretty out of date (Minor)

Lines 214-215: Need far more explanation about how exactly the life table model was implemented (Major)

Line 219-220: Can the authors comment on the plausibility of the changes in sugar purchased being maintained over the life course? Is there any evidence to back up this assumption? (Minor)

Line 226 - 228: This linear regression model needs far more explanation. What was the exact model specification? What was the exact sample it was run on? (Major)

Figure 2: I this figure difficult to interpret - it needs more explanation.

Line 309: The headline figure of "19,500 QALYs" is certainly eye catching, but I think it needs to be put into context (in relation to the child/adolescent population in England/UK). I'm not sure whether this is a small or large relative effect! (Major)

Lines 320-321: As before, I think more justification is needed for two separate papers (Minor)

Line 377: I think you could also discuss the representativeness of the dataset to the English/UK population - how big is the internal vs external validity trade off in this case? (Minor)

Reviewer #4: The study analyzes changes sugar purchased associated with the UK soft drink industry levy and modeled the effect on health in children and adolescents. The study is very relevant but needs to be revised.

I first recommend to change "effects or impact" by changes in or associations as in the absence of an experimental design, causal effects cannot be claimed for both the empirical estimation on sugar purchased and the model to estimate changes in dental caries and body mass index.

I understand that toiletries can be an adequate control but the authors should provide a convincing justification. It is crucial to test if the magnitude and trend prior to the implementation are not significantly different compared to SSB. If the test fails, toiletries is not an adequate control group. This can be done with ITSA models with a control group.

If the data set is at the household level, how was the specification for ITSA? Was it adapted to an ITSA? It is unclear as it seems that they are treating the data as time series given the autocorrelation test. I suggest to include the specification and provide a reference for ITSA models.

Why are they modeling only sugar purchases and not also volume purchased? Did all brands reformulated?

Is Kantar data nationally representative? What do you mean by "proprietary weight?

Why using an area level variable for socioeconomic status (SES) instead of household SES? How many missing data were in the data set? More than 10%? I suggest to provide results with and without the missing data.

The data is at the household level, I suggest to model purchases of sugar by adult equivalent or per capita and to adjust for household composition. Also, there are time varying macroeconomic variables that are associated with purchases, this should be included also.

In the results section, table 1, it is unclear how the estimations were derived from the ITSA model and if they included changes in level and slope.

Results for the third quintile are positive and unexpected. This should be addressed.

The time period covers the COVID-19 pandemic, if as in many countries there were changes in consumption patterns, this should be discussed and included in the model.

For the modeling exercise, what is the assumption for the duration of the intervention?

Any attachments provided with reviews can be seen via the following link:

[LINK]

Decision Letter 2

Philippa C Dodd

12 Jan 2024

Dear Dr. Scarborough,

Thank you very much for submitting your manuscript "Impact of the UK Soft Drinks Industry Levy on health and health inequalities in children and adolescents in England: an interrupted time series analysis and population health modelling study" (PMEDICINE-D-23-02980R2) for consideration at PLOS Medicine.

Your paper was evaluated by all the editors here. It was also discussed with an academic editor with relevant expertise, and sent to the statistical reviewer for re-review. The comments are appended at the bottom of this email and any accompanying reviewer attachments can be seen via the link below:

[LINK]

In light of the comments, we have invited you to undertake a further major revision. We cannot make any decision about publication until we have seen the revised manuscript and your response, and we plan to seek further re-review by the statistical reviewer.

In revising the manuscript for further consideration, your revisions should address the specific points made by each reviewer and the editors. Please also check the guidelines for revised papers at http://journals.plos.org/plosmedicine/s/revising-your-manuscript for any that apply to your paper. In your rebuttal letter you should indicate your response to the reviewers' and editors' comments, the changes you have made in the manuscript, and include either an excerpt of the revised text or the location (eg: page and line number) where each change can be found. Please submit a clean version of the paper as the main article file; a version with changes marked should be uploaded as a marked up manuscript.

In addition, we request that you upload any figures associated with your paper as individual TIF or EPS files with 300dpi resolution at resubmission; please read our figure guidelines for more information on our requirements: http://journals.plos.org/plosmedicine/s/figures. While revising your submission, please upload your figure files to the PACE digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at PLOSMedicine@plos.org.

We expect to receive your revised manuscript by Feb 02 2024 11:59PM. Please email us (plosmedicine@plos.org) if you have any questions or concerns.

***Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.***

We ask every co-author listed on the manuscript to fill in a contributing author statement, making sure to declare all competing interests. If any of the co-authors have not filled in the statement, we will remind them to do so when the paper is revised. If all statements are not completed in a timely fashion this could hold up the re-review process. If new competing interests are declared later in the revision process, this may also hold up the submission. Should there be a problem getting one of your co-authors to fill in a statement we will be in contact. YOU MUST NOT ADD OR REMOVE AUTHORS UNLESS YOU HAVE ALERTED THE EDITOR HANDLING THE MANUSCRIPT TO THE CHANGE AND THEY SPECIFICALLY HAVE AGREED TO IT. You can see our competing interests policy here: http://journals.plos.org/plosmedicine/s/competing-interests.

Please use the following link to submit the revised manuscript:

https://www.editorialmanager.com/pmedicine/

Your article can be found in the "Submissions Needing Revision" folder.

To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols

Please ensure that the paper adheres to the PLOS Data Availability Policy (see http://journals.plos.org/plosmedicine/s/data-availability), which requires that all data underlying the study's findings be provided in a repository or as Supporting Information. For data residing with a third party, authors are required to provide instructions with contact information for obtaining the data. PLOS journals do not allow statements supported by "data not shown" or "unpublished results." For such statements, authors must provide supporting data or cite public sources that include it.

We look forward to receiving your revised manuscript.

Sincerely,

Philippa Dodd, MBBS MRCP PhD

PLOS Medicine

plosmedicine.org

pdodd@plos.org

-----------------------------------------------------------

COMMENTS FROM THE ACADEMIC EDITOR

I think now it is much clearer, their methods, their controls, etc. I think they answered carefully all the comments. I liked the new appendix and the clarity of their analysis. However, I concur that a major revision is needed to address the statistical reviewer comments.

COMMENTS FROM THE EDITOR-IN-CHIEF

The authors must discuss the strength of the causal inference and provide details of how secular confounding was ruled out.

COMMENTS FROM THE EDITORS

GENERAL

Thank you for your detailed responses to previous editor and reviewer comments. Please see below for further comments including from the statistical reviewer which we require that you address in full.

Due to the concerns raised by the statistical reviewer and the potential impact on the overall message conveyed by your paper, we have invited a further major revision for you to address these.

When re-submitting your manuscript, please include a clean, untracked and unhighlighted version with all changes accepted as well as a tracked version.

DATA AVAILABILITY STATEMENT

Thank you for updating your statement. Please also include a URL for Kantar and a contact email address for data enquiries.

AUTHOR SUMMARY

Thank you for including an author summary.

As detailed previously, the author summary should constitute a non-technical summary of your research which makes findings accessible to a wide audience including both scientists and non-scientists. The author summary should consist of 2-3 succinct bullet points under each of the headings. The text should be distinct from the abstract.

In the final bullet point of ‘What Do These Findings Mean?’, please describe the main limitations of the study in non-technical language.

Please revise for brevity and improved accessibility to the non-scientist – we suggest removing all statistical information and describing your data in simple language.

METHODS and RESULTS

We agree with the statistical reviewer (please see below) that further explanation of the life table model should be included in the main text (as opposed to the supplementary files). Please include.

Lines 278, 287 & 300 – detail an ‘error’ related to citation of your supplementary files, perhaps confusion within the citation manager? Please check carefully throughout and amend this list is not exhaustive.

FIGURES

Figure 1 – please ensure that all abbreviations and symbols (including those for units of measurement) are clearly defined in a footnote.

ACKNOWLEDGEMENTS

Please remove this statement in light of there being ‘none’.

SUPPORTING INFORMATION

Throughout, please cite and label your Supporting Information (including individual tables and figures within the documents) as outlined here: https://journals.plos.org/plosmedicine/s/supporting-information

S2 text – please ensure that all abbreviations used in tables and figures are clearly defined in a footnote or the caption.

S2 text, S5 Fig – please clearly state the meaning of the lines over the bars for the reader.

S3 text - please amend formatting to figure labels S1 Fig as opposed to Figure S1.

COMMENTS FROM THE STATISTICAL REVIEWER:

Reviewer #3: Thank you to the authors for replying in detail to the comments from myself and the other reviewers. There are still several (fairly major) aspects of the paper that I think need to be addressed before publication can be considered.

1. Similarity of this paper to the Rogers et al paper

I am still not convinced that this paper is different enough in its current format from the Rogers et al paper to justify a standalone paper. I will leave this issue to the journal editor(s).

2. Missing Data

Given the responses to my comment regarding missing data and the comment from Reviewer 4, I think a complete should definitely be presented as part of a sensitivity analysis. The fact that the missing data is by coincidence very much restricted to the pre-announcement phase of the study and therefore has a significant effect on the counterfactual is not a good enough excuse for not including this sensitivity analysis.

3. How the optimal ITSA model was chosen

I am still not clear how the optimal ITSA was chosen on the basis of the AIC. Please be explicit and state how many different models were run, and the autoregressive order (p), moving average order (q) and AIC of the final model. Include this information either in the main text or (more likely) in the supplementary materials.

4. Lifetable Modelling Approach

I am still not convinced by the life table modelling approach used in the paper given the complexity of obesity as a disease area. Please include further discussion of the limitations of this life table modelling approach in the context of obesity.

5. Combining QALY impact of BMI and Dental Caries in a "multiplicative way"

The measurement and valuation of utility values is one of my research interests, and I've personally never heard of utilities being combined in a "multiplicative way". Please further justify this method, including references to both theoretical and applied paper (if applicable).

6. Explanation of the life table model in the main text

I still think further explanation of the life table model is needed in the main text, not the supplementary file. This is a key part of the paper.

Any attachments provided with reviews can be seen via the following link:

[LINK]

Decision Letter 3

Philippa C Dodd

28 Feb 2024

Dear Dr. Scarborough,

Thank you very much for re-submitting your manuscript "Impact of the UK Soft Drinks Industry Levy on health and health inequalities in children and adolescents in England: an interrupted time series analysis and population health modelling study" (PMEDICINE-D-23-02980R3) for review by PLOS Medicine.

I have discussed the paper with my colleagues and the academic editor and it was also seen again by the statistical reviewer. I am pleased to say that provided the remaining editorial and production issues are dealt with we are planning to accept the paper for publication in the journal.

The remaining issues that need to be addressed are listed at the end of this email. Any accompanying reviewer attachments can be seen via the link below. Please take these into account before resubmitting your manuscript:

[LINK]

***Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.***

In revising the manuscript for further consideration here, please ensure you address the specific points made by each reviewer and the editors. In your rebuttal letter you should indicate your response to the reviewers' and editors' comments and the changes you have made in the manuscript. Please submit a clean version of the paper as the main article file. A version with changes marked must also be uploaded as a marked up manuscript file.

Please also check the guidelines for revised papers at http://journals.plos.org/plosmedicine/s/revising-your-manuscript for any that apply to your paper. If you haven't already, we ask that you provide a short, non-technical Author Summary of your research to make findings accessible to a wide audience that includes both scientists and non-scientists. The Author Summary should immediately follow the Abstract in your revised manuscript. This text is subject to editorial change and should be distinct from the scientific abstract.

We expect to receive your revised manuscript within 1 week. Please email us (plosmedicine@plos.org) if you have any questions or concerns.

We ask every co-author listed on the manuscript to fill in a contributing author statement. If any of the co-authors have not filled in the statement, we will remind them to do so when the paper is revised. If all statements are not completed in a timely fashion this could hold up the re-review process. Should there be a problem getting one of your co-authors to fill in a statement we will be in contact. YOU MUST NOT ADD OR REMOVE AUTHORS UNLESS YOU HAVE ALERTED THE EDITOR HANDLING THE MANUSCRIPT TO THE CHANGE AND THEY SPECIFICALLY HAVE AGREED TO IT.

Please ensure that the paper adheres to the PLOS Data Availability Policy (see http://journals.plos.org/plosmedicine/s/data-availability), which requires that all data underlying the study's findings be provided in a repository or as Supporting Information. For data residing with a third party, authors are required to provide instructions with contact information for obtaining the data. PLOS journals do not allow statements supported by "data not shown" or "unpublished results." For such statements, authors must provide supporting data or cite public sources that include it.

To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript.

Please note, when your manuscript is accepted, an uncorrected proof of your manuscript will be published online ahead of the final version, unless you've already opted out via the online submission form. If, for any reason, you do not want an earlier version of your manuscript published online or are unsure if you have already indicated as such, please let the journal staff know immediately at plosmedicine@plos.org.

If you have any questions in the meantime, please contact me at pdodd@plos.org or the journal staff on plosmedicine@plos.org.  

We look forward to receiving the revised manuscript by Mar 06 2024 11:59PM.   

Kind regards,

Pippa

Philippa Dodd, MBBS MRCP PhD

PLOS Medicine

plosmedicine.org

pdodd@plos.org

------------------------------------------------------------

Requests from Editors:

GENERAL

Thank you for your detailed and considered responses to previous editor and reviewer comments. Please see below for further comments which we require you address prior to publication.

DATA AVAILABILITY

PLOS is committed to Open Science practices and transparent data reporting. In line with those commitments, PLOS Medicine has strict policies regarding data availability.

We require that the company name (Kantar) and the URL are provided. It is vital that the reader is made aware of the origins of the dataset used for your study. We also require a contact email address for data inquiries, please note that this cannot be a study author. Please update your statement in the manuscript submission form.

* This is a prerequisite to publication, and we cannot proceed without this information *

Please also include, as supporting information, the relevant documentation from Kantar which states their previous and now updated policy.

AUTHOR SUMMARY

Line 70 – sentence beginning, ‘while children and…’ suggest making into a separate bullet point beginning, ‘Children and…’ as we think is an important point to make and should be emphasized.

METHODS and RESULTS

We agree with the statistical reviewer, please see below, that it would be beneficial to include the results without multiple imputation as supporting information, alongside a brief note in the main text of the results section.

Line 289 – please correct the ‘table 1 error. Reference source not found’.

DISCUSSION

As per the statistical reviewer’s request, please discuss the limitations of the lifetable model.

SUPPORTING INFORMATION

As above, please include Kantar’s data policies.

As above, please include results without imputation as supporting information, per the statistical reviewer’s request.

S2 Text:

1) Page 5 – please define ‘DMFT’ at first use here, apologies if I have missed it previously.

2) Figures – please define ‘IMD’ in the footnotes of all figures.

SOCIAL MEDIA

To help us extend the reach of your research, please detail any X (formerly Twitter) handles you wish to be included when we tweet this paper (including your own, your coauthors’, your institution, funder, or lab) in the manuscript submission form when you re-submit the manuscript.

Comments from Reviewers:

Reviewer #3: Thank you to the authors for replying to my concerns. I have a couple of (very) minor things that I think should be changed before publication:

Missing Data

Thank you to the authors for providing these additional results. Please can the additional results provided by the authors (without multiple imputation) be included as part of the supplementary materials and a sentence added to main text noting that these results are included. I think it's important that these are included and referenced in the paper.

Lifetable Modelling Approach

As noted in my previous review (R3), please can the authors include a sentence or two discussing the potential limitations with their modelling approach in the main text.

After these minor changes have been done I'll be happy to approve the manuscript for publication.

Any attachments provided with reviews can be seen via the following link:

[LINK]

Decision Letter 4

Philippa C Dodd

6 Mar 2024

Dear Dr Scarborough, 

On behalf of my colleagues and the Academic Editor, Professor Barry Popkin, I am pleased to inform you that we have agreed to publish your manuscript "Impact of the UK Soft Drinks Industry Levy on health and health inequalities in children and adolescents in England: an interrupted time series analysis and population health modelling study" (PMEDICINE-D-23-02980R4) in PLOS Medicine.

We thank you for your responsiveness to previous comments. Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. Please be aware that it may take several days for you to receive this email; during this time no action is required by you. Once you have received these formatting requests, please note that your manuscript will not be scheduled for publication until you have made the required changes.

In the meantime, please log into Editorial Manager at http://www.editorialmanager.com/pmedicine/, click the "Update My Information" link at the top of the page, and update your user information to ensure an efficient production process. 

PRESS

We frequently collaborate with press offices. If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximise its impact. If the press office is planning to promote your findings, we would be grateful if they could coordinate with medicinepress@plos.org. If you have not yet opted out of the early version process, we ask that you notify us immediately of any press plans so that we may do so on your behalf.

We also ask that you take this opportunity to read our Embargo Policy regarding the discussion, promotion and media coverage of work that is yet to be published by PLOS. As your manuscript is not yet published, it is bound by the conditions of our Embargo Policy. Please be aware that this policy is in place both to ensure that any press coverage of your article is fully substantiated and to provide a direct link between such coverage and the published work. For full details of our Embargo Policy, please visit http://www.plos.org/about/media-inquiries/embargo-policy/.

To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols

Thank you again for submitting to PLOS Medicine. We look forward to publishing your paper. 

Kind regards,

Pippa 

Philippa C. Dodd, MBBS MRCP PhD 

PLOS Medicine

pdodd@plos.org

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Text. Interrupted time series analysis.

    (DOCX)

    pmed.1004371.s001.docx (19.6KB, docx)
    S2 Text. Lifetable analysis data inputs.

    (DOCX)

    pmed.1004371.s002.docx (5.4MB, docx)
    S3 Text. Additional results.

    (DOCX)

    pmed.1004371.s003.docx (511.1KB, docx)
    Attachment

    Submitted filename: Response to reviewers.docx

    pmed.1004371.s004.docx (58.6KB, docx)
    Attachment

    Submitted filename: Response to reviewers.docx

    pmed.1004371.s005.docx (513.1KB, docx)

    Data Availability Statement

    The data that support the PRIMEtime model are freely available from the following sources: o Global Burden of Disease Project (https://vizhub.healthdata.org/gbd-results/) o Office for National Statistics (https://vizhub.healthdata.org/gbd-results/) o Health Survey for England (https://digital.nhs.uk/data-and-information/publications/statistical/health-survey-for-england) o Children’s Dental Health Survey 2013 (https://digital.nhs.uk/data-and-information/publications/statistical/children-s-dental-health-survey/child-dental-health-survey-2013-england-wales-and-northern-ireland) o Adult’s Dental Health Survey 2009 (https://digital.nhs.uk/data-and-information/publications/statistical/adult-dental-health-survey/adult-dental-health-survey-2009-summary-report-and-thematic-series) The interrupted time series analyses uses commercial data purchased from Kantar Fast Moving Consumer Goods Panel and cannot be shared without permission from the data owners. Data requests can be submitted to Kantar using the online contact us form found here: https://www.kantar.com/contact/hq-general-contact.


    Articles from PLOS Medicine are provided here courtesy of PLOS

    RESOURCES